Login to Your Account

Third quarter ends with a bang, not a whimper: European biotechs raise $837M

By Cormac Sheridan
Staff Writer

Monday, October 2, 2017

DUBLIN – A flurry of deals in late September added a burst of energy to what was otherwise a pretty sleepy third quarter for European biotech firms engaged in drug development. The last week of the month – and of the quarter – was a particularly busy one. European firms raised $472 million during that time, more than half of the total third-quarter raise, which came to $837 million.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription